NTLA Stock: The $24 Price Target Nobody's Talking About (Intellia Therapeutics 2027 PDUFA)
1 extracted signal · 0 resolved · 1 still active
Global News DailyIndependent analyst profile- Source published
- 18 Sept 2026, 12:36 UTC
- Recorded by Tahlil Plus
- 18 Sept 2026, 16:08 UTC
AI-generated source summary
The analysis of NTLA highlights a classic biotech binary situation, driven by a significant gap between its revolutionary science and the commercial realities of the healthcare market. The stock, currently trading at $11.77, is seen as pricing in substantial doubt. Key catalysts to watch include the FDA PDUFA decision for Ionvo-z in March 2027, expected commercial launch in H1 2027, potential Phase 3 data for 'nex-z' in late 2027, and the end of cash runway guidance in 2028. The company has $628.4M in cash as of Q2 2026 and secured up to $400M in debt financing from OrbiMed, extending its runway into 2028 without immediate equity dilution. However, the bear case centers on insurance reluctance and a small US market for its primary indication. The Nex-z program faced clinical holds following a patient death, leading to new HLA typing for patient screening. Analyst consensus shows a 'significant bearish cohort,' with 40% of shares potentially shorted, requiring 13 days to cover at average trading volumes. Price targets range widely from $5 to $68, reflecting high volatility and a beta of 1.82. The upcoming PDUFA decision is identified as the moment of truth, which could significantly shift market sentiment and unlock the stock's potential.
AI-generated summary based on the source content.
Signal outcomes at a glance
Tracking LiveSignals in this source
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
1 eligible signal linked to this case.
- Source processing completed
Source analysis and structured extraction completed.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
- Live evaluation in progress
1 signal remains active.
Global News Daily
Platform-wide history, separate from this source evaluation.
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.